Principia Biopharma Inc. (PRNB) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
220 EAST GRAND AVENUE SOUTH SAN FRANCISCO, CA 94080 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 6/30/2020 Q2 | 3/31/2020 Q1 | 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 311,469 | 315,580 | 150,704 | 169,565 | 163,619 | 176,925 | |||
| Cash and cash equivalents | 59,427 | 39,537 | 29,411 | 41,073 | 14,670 | 34,489 | |||
| Short-term investments | 252,042 | 276,043 | 121,293 | 128,492 | 148,949 | 142,436 | |||
| Restricted cash and investments | 82 | ||||||||
| Receivables | |||||||||
| Prepaid expense | 3,112 | 2,893 | 957 | 1,417 | 2,465 | 1,661 | |||
| Other undisclosed current assets | 1,515 | 1,272 | 701 | 740 | 829 | 2,104 | |||
| Total current assets: | 316,096 | 319,745 | 152,362 | 171,722 | 166,913 | 180,772 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 6,624 | ✕ | |||||||
| Property, plant and equipment | 9,363 | 9,687 | 10,165 | 10,598 | 10,671 | 1,666 | |||
| Long-term investments and receivables | 29,645 | 52,257 | 10,513 | 8,972 | 3,712 | ||||
| Long-term investments | 29,645 | 52,257 | 10,513 | 8,972 | 3,712 | ||||
| Restricted cash and investments | 567 | 567 | 567 | 567 | 567 | 567 | |||
| Other noncurrent assets | 480 | 480 | 480 | 480 | 480 | 8,804 | |||
| Total noncurrent assets: | 46,679 | 62,991 | 21,725 | 20,617 | 11,718 | 14,749 | |||
| TOTAL ASSETS: | 362,775 | 382,736 | 174,087 | 192,339 | 178,631 | 195,521 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 5,827 | 9,167 | 7,293 | 7,493 | 7,364 | 9,744 | |||
| Employee-related liabilities | 3,248 | 6,715 | 4,350 | 2,850 | 2,224 | 4,312 | |||
| Accounts payable | 1,623 | 1,850 | 2,323 | 4,052 | 4,182 | 4,439 | |||
| Accrued liabilities | 956 | 602 | 620 | 591 | 958 | 993 | |||
| Debt | 1,829 | ||||||||
| Deferred rent credit | 1,181 | 1,156 | 1,132 | 1,105 | |||||
| Other undisclosed current liabilities | 10,365 | 5,791 | 5,047 | 4,823 | 2,680 | 7,136 | |||
| Total current liabilities: | 18,021 | 16,139 | 13,496 | 13,448 | 11,149 | 16,880 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation: | 13,306 | ||||||||
| Liabilities, other than long-term debt | 7,619 | 7,916 | 8,213 | 8,492 | 8,781 | ||||
| Deferred rent credit | 7,619 | 7,916 | 8,213 | 8,492 | 8,781 | ||||
| Operating lease, liability | 13,306 | ✕ | |||||||
| Total noncurrent liabilities: | 13,306 | 7,619 | 7,916 | 8,213 | 8,492 | 8,781 | |||
| Total liabilities: | 31,327 | 23,758 | 21,412 | 21,661 | 19,641 | 25,661 | |||
| Equity | |||||||||
| Equity, attributable to parent | 331,448 | 358,978 | 152,675 | 170,678 | 158,990 | 169,860 | |||
| Common stock | 3 | 3 | 2 | 2 | 2 | 2 | |||
| Additional paid in capital | 549,622 | 544,709 | 313,414 | 309,088 | 304,605 | 302,393 | |||
| Accumulated other comprehensive income (loss) | 65 | 9 | 78 | 111 | 21 | (128) | |||
| Accumulated deficit | (218,242) | (185,743) | (160,819) | (138,523) | (145,638) | (132,407) | |||
| Total equity: | 331,448 | 358,978 | 152,675 | 170,678 | 158,990 | 169,860 | |||
| Other undisclosed liabilities and equity | |||||||||
| TOTAL LIABILITIES AND EQUITY: | 362,775 | 382,736 | 174,087 | 192,339 | 178,631 | 195,521 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 6/30/2020 Q2 | 3/31/2020 Q1 | 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 30,000 | 5,160 | 26,137 | |||||
| Gross profit: | 30,000 | 5,160 | 26,137 | |||||
| Operating expenses | (34,111) | (26,611) | (23,333) | (23,951) | (20,031) | (17,875) | ||
| Operating income (loss): | (34,111) | (26,611) | (23,333) | 6,049 | (14,871) | 8,262 | ||
| Nonoperating income | 1,612 | 1,687 | 1,037 | 1,066 | 1,184 | 1,115 | ||
| Investment income, nonoperating | 1,612 | 1,034 | 1,108 | 1,183 | ||||
| Other nonoperating income (expense) | 3 | (42) | 1 | |||||
| Income (loss) from continuing operations before income taxes: | (32,499) | (24,924) | (22,296) | 7,115 | (13,687) | 9,377 | ||
| Other undisclosed loss from continuing operations | (1) | |||||||
| Income (loss) from continuing operations: | (32,499) | (24,924) | (22,296) | 7,115 | (13,687) | 9,376 | ||
| Income (loss) before gain (loss) on sale of properties: | (32,499) | (24,924) | (22,296) | 7,115 | (13,687) | 9,376 | ||
| Other undisclosed net income | 1 | |||||||
| Net income (loss) attributable to parent: | (32,499) | (24,924) | (22,296) | 7,115 | (13,687) | 9,377 | ||
| Undistributed earnings (loss) allocated to participating securities, basic | (4,460) | |||||||
| Net income (loss) available to common stockholders, diluted: | (32,499) | (24,924) | (22,296) | 7,115 | (13,687) | 4,917 | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 6/30/2020 Q2 | 3/31/2020 Q1 | 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (32,499) | (24,924) | (22,296) | 7,115 | (13,687) | 9,377 | ||
| Comprehensive income (loss): | (32,499) | (24,924) | (22,296) | 7,115 | (13,687) | 9,377 | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 56 | (69) | (33) | 90 | 149 | (28) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (32,443) | (24,993) | (22,329) | 7,205 | (13,538) | 9,349 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.